Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06748950 · ClinicalTrials.gov registry record · NA
Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling
A NA study, sponsored by Stanford University.
- Not yet
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT06748950: Clinical Trial NA study, sponsored by Stanford University.
NCT06748950 is a NA study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06748950, a NA study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive disorder.
Interventions
- OTHER LCHF Ketogenic Diet
- OTHER Diet-as-Usual (DAU)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-07 |
| Est. Completion | 2028-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06748950
The ClinicalTrials.gov registry entry for NCT06748950 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LCHF Ketogenic Diet is the first listed.
NCT06748950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06748950 about?
NCT06748950 is a clinical study titled "Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling". The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive disorder.
What is the current status of trial NCT06748950?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-07. Estimated completion is 2028-07.
What interventions are being tested in trial NCT06748950?
The interventions under investigation include: LCHF Ketogenic Diet (OTHER), Diet-as-Usual (DAU) (OTHER).
Who is sponsoring clinical trial NCT06748950?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.